title: The influence of cisplatin, doxorubicin, pegylated doxorubicin, oxaliplatin and gemcitabine on mahlavu cell line.
abstract: OBJECTIVE
  Hepatocellar carcinoma (HCC) remains a major health problem being the third leading cause of deaths due to cancer worldwide. Because HCC is known to be highly resistant to conventional systemic therapies, single-agent or combination of systemic therapies have been investigated. Today, sorafenib, a multikinase inhibitor, is the only approved systemic agent for the first line treatment of advanced HCC. In this study, we aimed to investigate the influence of different concentrations of cisplatin, doxorubicin, pegylated doxorubicin (PLD), oxaliplatin and gemcitabine by applying these agents either single or in combinations on mahlavu cell line.
  
  
  METHODS
  HCC mahlavu cell line was used for the experiments. Cell death was measured by flow cytometry at 48 hrs after incubation with various concentrations (0.1 μg/ml, 1.0 μg/ml and 10 μg/ml) of the drugs.
  
  
  RESULTS
  Cell death due to gemcitabine was found to be significantly higher than cell deaths caused by the other single agents including cisplatin, oxaliplatin, doxorubicin and PLD (p<0.001, p<0.001, p<0.001 and p=0.0049, respectively). There was no significant difference between gemcitabine and both the gemcitabine combination with doxorubicin and PLD (p=0.992 and p=0.441, respectively).
  
  
  CONCLUSIONS
  This is a preliminary analysis evaluating the effect of the conventional chemotherapeutic agents on mahlavu cell line in vitro. The findings of this study suggest that gemcitabine-based therapies keep on being the prefered therapeutic approach for the treatment of HCC.
authors.affiliation: Bulent Ecevit University, Faculty of Medicine, 1Department of Internal Medicine, Zonguldak, Turkey.
authors.forename: Sevil
authors.initials: S
authors.lastname: Uygun Ilikhan
authors.forename: Muammer
authors.initials: M
authors.lastname: Bilici
authors.forename: Hatice
authors.initials: H
authors.lastname: Sahin
authors.forename: Ayse
authors.initials: A
authors.lastname: Semra Demir Akca
authors.forename: Huseyin
authors.initials: H
authors.lastname: Engin
authors.forename: Cemil
authors.initials: C
authors.lastname: Bilir
authors.forename: Nergis
authors.initials: N
authors.lastname: Sevinc
authors.forename: Nil
authors.initials: N
authors.lastname: Banu Pelit
authors.forename: Ishak
authors.initials: I
authors.lastname: Ozel Tekin
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000473:pathology; D045744:Cell Line, Tumor; D002945:Cisplatin / Q000494:pharmacology; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000494:pharmacology; D004317:Doxorubicin / Q000494:pharmacology; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000473:pathology; D009944:Organoplatinum Compounds / Q000494:pharmacology; D000077150:Oxaliplatin; D000093542:Gemcitabine
chemical_list: D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D003841:Deoxycytidine; D004317:Doxorubicin; D002945:Cisplatin; D000093542:Gemcitabine